An article in the New England Journal of Medicine (Volume 394, Number 11, Pages 1125-1126, March 12/19, 2026) discusses thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia. These drugs stimulate the formation of platelets by binding to the thrombopoietin receptor. They are used to treat low platelet counts caused by chemotherapy in cancer patients. The article discusses their efficacy and safety in this indication. It cites specific clinical trials that have shown an increase in platelet counts and a reduction in the need to delay chemotherapy. The main findings include a significant improvement in hematological parameters without serious adverse effects. These agonists represent a new option in the management of chemotherapy thrombocytopenia.